Gonadotropin-Releasing Hormone
"Gonadotropin-Releasing Hormone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
| Descriptor ID |
D007987
|
| MeSH Number(s) |
D06.472.699.327.740.320 D12.644.400.400.740.320 D12.644.456.460 D12.644.548.365.740.320 D12.776.631.650.405.740.320
|
| Concept/Terms |
Gonadotropin-Releasing Hormone- Gonadotropin-Releasing Hormone
- Gonadotropin Releasing Hormone
- Gn-RH
- Gonadoliberin
- LHFSH Releasing Hormone
- Releasing Hormone, LHFSH
- LH-RH
- LFRH
- LH-Releasing Hormone
- LH Releasing Hormone
- LH-FSH Releasing Hormone
- LH FSH Releasing Hormone
- LHFSHRH
- LHRH
- Luliberin
- Gonadorelin
- Luteinizing Hormone-Releasing Hormone
- Luteinizing Hormone Releasing Hormone
- FSH-Releasing Hormone
- FSH Releasing Hormone
- GnRH
|
Below are MeSH descriptors whose meaning is more general than "Gonadotropin-Releasing Hormone".
Below are MeSH descriptors whose meaning is more specific than "Gonadotropin-Releasing Hormone".
This graph shows the total number of publications written about "Gonadotropin-Releasing Hormone" by people in this website by year, and whether "Gonadotropin-Releasing Hormone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 4 | 2 | 6 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gonadotropin-Releasing Hormone" by people in Profiles.
-
A systematic approach to the management of menses prophylaxis and suppression in pre-menopausal hematologic cancer patients. J Oncol Pharm Pract. 2024 Oct; 30(7):1259-1267.
-
Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103.
-
Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) - protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open. 2024 01 12; 14(1):e078989.
-
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids - current roles and future perspectives. Expert Opin Pharmacother. 2023 Sep-Dec; 24(16):1799-1809.
-
An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
-
Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022 Apr; 21(4):477-486.
-
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
-
Accelerating functional gene discovery in osteoarthritis. Nat Commun. 2021 01 20; 12(1):467.
-
Assessment of children in the autistic spectrum disorder that carry the Thr92Ala-DIO2 polymorphism. J Endocrinol Invest. 2021 Aug; 44(8):1775-1782.
-
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.